Printer Friendly

IMMUCOR TO CONTINUE BLOOD BANK AUTOMATION DEVELOPMENT PROJECT

 IMMUCOR TO CONTINUE BLOOD BANK AUTOMATION DEVELOPMENT PROJECT
 NORCROSS, Ga., Sept. 28 /PRNewswire/ -- Immucor, Inc. (NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today the completion of the engineering feasibility study for the blood bank automated instrument being developed jointly with Bio-Tek Instruments, Inc.
 Immucor also announced its intention to fund the development effort, subject to the signing of a definitive agreement between the two companies. Bio-Tek will be responsible for engineering, software development and manufacturing. The instrument will use Immucor's proprietary Capture(R) product technology to perform blood bank patient testing, and Immucor will market the instrument worldwide.
 The project is expected to take approximately two years to complete, with a research and development cost to Immucor of $3.3 million. Immucor intends to fund 100 percent of the project cost, rather than 85 percent as previously stated. As a result, Bio-Tek has reduced Immucor's transfer price for the instrument.
 Commenting on the instrument project, Edward L. Gallup, president of Immucor, Inc. said: "Although research and development spending will increase significantly over the next two years, we believe this project will enable us to realize the full potential of our Capture products technology -- a fully automated, or 'walk away,' instrument designed for the hospital blood bank laboratory to perform routine patient testing now done manually by blood bank technologists."
 Gallup also noted Immucor believes the potential worldwide market for such an instrument-reagent system is $200 million.
 Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. Founded in 1968, privately held Bio-Tek is a leader in the design and manufacturing of medical instrumentation and related software.
 -0- 9/28/92
 /CONTACT: Richard J. Still, senior vice president-Finance of Immucor, 404-441-2051/
 (BLUD) CO: Immucor, Inc.; Bio-Tek Instruments, Inc. ST: Georgia IN: MTC SU:


BR-EA -- AT001 -- 3805 09/28/92 08:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 28, 1992
Words:342
Previous Article:ICL PARTICIPATES IN MAJOR EC-FUNDED TECHNOLOGY DEVELOPMENT, AWARDED FIVE ESPRIT CONTRACTS
Next Article:YORK INTERNATIONAL ACQUIRES MILLER-PICKING CORPORATION
Topics:


Related Articles
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS
IMMUCOR REPORTS FIRST QUARTER RESULTS
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS
IMMUCOR REPORTS SECOND QUARTER RESULTS
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR FILES 510(k) APPLICATION FOR ABS2000
ABS2000 ANALYZER CLEARED FOR SALE INTO CANADA
Clinical Trials Begin For Immucor's Second Automated Blood Analyzer -- The ABS(HV)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters